NeuroHealing Pharmaceuticals Announces IND Clearance for NH001 to Improve The Outcome of Patients in a Vegetative State Following a Traumatic Brain Injury

Newton, Mass., January 17, 2006 NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a 76-patients, Phase II clinical trial with NH001. The study is entitled “A Double-Blind, Placebo-Controlled, Randomized…